Patents by Inventor Andrew L. Zeitlin

Andrew L. Zeitlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130109719
    Abstract: Methods for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS while minimizing drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential by administration of d-threo-methylphenidate or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: December 20, 2012
    Publication date: May 2, 2013
    Inventors: Andrew L. Zeitlin, Maghsoud M. Dariani, David L. Stirling
  • Publication number: 20130053414
    Abstract: In one aspect, the present invention is directed to methods for treating fatigue, neurobehavioral slowing and other cognitive disorders and defects due to cancers and treatments associated with cancers, and similar conditions. In a further aspect, the present invention is directed to methods for treating disorders related to menopause, including executive function defects. The methods involve the administration of a composition comprising D-threo methylphenidate that is substantially free of L-threo methylphenidate and of erythro forms of methylphenidate.
    Type: Application
    Filed: October 26, 2012
    Publication date: February 28, 2013
    Inventors: Jerome B. Zeldis, Herbert J. Faleck, Vikram Khetani, Andrew L. Zeitlin, Maghsoud M. Dariani, David I. Stirling
  • Publication number: 20110257227
    Abstract: In one aspect, the present invention is directed to methods for treating fatigue, neurobehavioral slowing and other cognitive disorders and defects due to cancers and treatments associated with cancers, and similar conditions. In a further aspect, the present invention is directed to methods for treating disorders related to menopause, including executive function defects. The methods involve the administration of a composition comprising D-threo methylphenidate that is substantially free of L-threo methylphenidate and of erythro forms of methylphenidate.
    Type: Application
    Filed: June 30, 2011
    Publication date: October 20, 2011
    Inventors: Jerome B. ZELDIS, Herbert J. FALECK, Vikram KHETANI, Andrew L. ZEITLIN, Maghsoud M. DARIANI, David I. STIRLING
  • Publication number: 20110201645
    Abstract: Methods for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS while minimizing drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential by administration of d-threo-methylphenidate or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: April 26, 2011
    Publication date: August 18, 2011
    Inventors: Andrew L. Zeitlin, Maghsoud M. Dariani, David I. Stirling
  • Publication number: 20100093797
    Abstract: In one aspect, the present invention is directed to methods for treating fatigue, neurobehavioral slowing and other cognitive disorders and defects due to cancers and treatments associated with cancers, and similar conditions. In a further aspect, the present invention is directed to methods for treating disorders related to menopause, including executive function defects. The methods involve the administration of a composition comprising D-threo methylphenidate that is substantially free of L-threo methylphenidate and of erythro forms of methylphenidate.
    Type: Application
    Filed: December 17, 2009
    Publication date: April 15, 2010
    Inventors: Jerome B. Zeldis, Herbert J. Faleck, Vikram Khetani, Andrew L. Zeitlin, Maghsoud M. Dariani, David I. Stirling
  • Publication number: 20100035928
    Abstract: Methods for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS while minimizing drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential by administration of d-threo-methylphenidate or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: October 16, 2009
    Publication date: February 11, 2010
    Inventors: Andrew L. Zeitlin, Maghsoud M. Dariani, David L. Stirling
  • Publication number: 20090088455
    Abstract: Chronic bolus administration of D-threo methylphenidate is provided. The administration of the D-threo isomer eliminates adverse side effects associated with the DL racemate, and provides improved effectiveness. The compositions and methods of the invention are useful in treating nervous system disorders including attention deficit disorder, attention deficit hyperactivity disorder, and cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome.
    Type: Application
    Filed: December 9, 2008
    Publication date: April 2, 2009
    Applicant: Celgene Corporation
    Inventors: Maghsoud M. Dariani, Andrew L. Zeitlin, Jerome B. Zeldis
  • Patent number: 7435726
    Abstract: This invention relates to compositions comprising thalidomide and another anti-cancer drug which can be used in the treatment or prevention of cancer. Preferred anti-cancer drugs are topoisomerase inhibitors. A particular composition comprises thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and irinotecan. The invention also relates to methods of treating or preventing cancer which comprise the administration of a thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of chemotherapy or radiation therapy which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: October 14, 2008
    Assignee: Celgene Corporation
    Inventors: Jerome B. Zeldis, Andrew L. Zeitlin, Sol Barer
  • Patent number: 7431944
    Abstract: Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release profile, the dosage forms eliminate the need for a patient to carry an additional dose for ingestion during the day. The dosage forms and methods provided are useful in administering methylphenidate and pharmaceutically acceptable salts thereof, which generally require one or more doses throughout the day.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: October 7, 2008
    Assignee: Celgene Corporation
    Inventors: Atul M. Mehta, Andrew L. Zeitlin, Maghsoud M. Dariani
  • Patent number: 7115631
    Abstract: In one aspect, the present invention is directed to methods for treating fatigue, neurobehavioral slowing and other cognitive disorders and defects due to cancers and treatments associated with cancers, and similar conditions. In a further aspect, the present invention is directed to methods for treating disorders related to menopause, including executive function defects. The methods involve the administration of a composition comprising D-threo methylphenidate that is substantially free of L-threo methylphenidate and of erythro forms of methylphenidate.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: October 3, 2006
    Assignee: Celgene Corporation
    Inventors: Jerome B Zeldis, Herbert J. Faleck, Vikram Khetani, Andrew L. Zeitlin, Maghsoud M. Dariani, David Sterling
  • Publication number: 20040204456
    Abstract: In one aspect, the present invention is directed to methods for treating fatigue, neurobehavioral slowing and other cognitive disorders and defects due to cancers and treatments associated with cancers, and similar conditions. In a further aspect, the present invention is directed to methods for treating disorders related to menopause, including executive function defects. The methods involve the administration of a composition comprising D-threo methylphenidate that is substantially free of L-threo methylphenidate and of erythro forms of methylphenidate.
    Type: Application
    Filed: April 8, 2004
    Publication date: October 14, 2004
    Applicant: Celgene Corporation
    Inventors: Jerome B. Zeldis, Andrew L. Zeitlin, Herbert J. Faleck, Vikram Khetani, Magsoud M. Dariani, David I. Sterling
  • Publication number: 20040091532
    Abstract: Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release profile, the dosage forms eliminate the need for a patient to carry an additional dose for ingestion during the day. The dosage forms and methods provided are useful in administering methylphenidate and pharmaceutically acceptable salts thereof, which generally require one or more doses throughout the day.
    Type: Application
    Filed: June 10, 2003
    Publication date: May 13, 2004
    Inventors: Atul M. Mehta, Andrew L. Zeitlin, Maghsoud M. Dariani
  • Publication number: 20030232857
    Abstract: Chronic bolus administration of D-threo methylphenidate is provided. The administration of the D-threo isomer eliminates adverse side effects associated with the DL racemate, and provides improved effectiveness. The compositions and methods of the invention are useful in treating nervous system disorders including attention deficit disorder, attention deficit hyperactivity disorder, and cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome.
    Type: Application
    Filed: March 24, 2003
    Publication date: December 18, 2003
    Inventors: Maghsoud M. Dariani, Andrew L. Zeitlin, Jerome B. Zeldis
  • Patent number: 6635284
    Abstract: Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release profile, the dosage forms eliminate the need for a patient to carry an additional dose for ingestion during the day. The dosage forms and methods provided are useful in administering methylphenidate and pharmaceutically acceptable salts thereof, which generally require one or more doses throughout the day.
    Type: Grant
    Filed: March 11, 1998
    Date of Patent: October 21, 2003
    Assignee: Celegene Corporation
    Inventors: Atul M. Mehta, Andrew L. Zeitlin, Maghsoud M. Dariani
  • Patent number: 6602887
    Abstract: Chronic bolus administration of D-threo methylphenidate is provided. The administration of the D-threo isomer eliminates adverse side effects associated with the DL racemate, and provides improved effectiveness. The compositions and methods of the invention are useful in treating nervous system disorders including attention deficit disorder, attention deficit hyperactivity disorder, and cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: August 5, 2003
    Assignee: Celegene Corporation
    Inventors: Maghsoud M. Dariani, Andrew L. Zeitlin, Jerome B. Zeldis
  • Publication number: 20030113373
    Abstract: Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release profile, the dosage forms eliminate the need for a patient to carry an additional dose for ingestion during the day. The dosage forms and methods provided are useful in administering methylphenidate and pharmaceutically acceptable salts thereof, which generally require one or more doses throughout the day.
    Type: Application
    Filed: March 11, 1998
    Publication date: June 19, 2003
    Inventors: ATUL M. MEHTA, ANDREW L. ZEITLIN, MAGHSOUD M. DARIANI
  • Patent number: 6528530
    Abstract: Phenidate drug formulations are provided having reduced potential for drug abuse. Dosage forms for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS are provided which minimize drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential. Such dosage forms comprise D-threo stereoisomer of a phenidate in the substantial absence of all other stereoisomers.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: March 4, 2003
    Assignee: Celgene Corporation
    Inventors: Andrew L. Zeitlin, Maghsoud M. Dariani
  • Publication number: 20020198234
    Abstract: In one aspect, the present invention is directed to methods for treating fatigue, neurobehavioral slowing and other cognitive disorders and defects due to cancers and treatments associated with cancers, and similar conditions. In a further aspect, the present invention is directed to methods for treating disorders related to menopause, including executive function defects. The methods involve the administration of a composition comprising D-threo methylphenidate that is substantially free of L-threo methylphenidate and of erythro forms of methylphenidate.
    Type: Application
    Filed: July 16, 2002
    Publication date: December 26, 2002
    Applicant: WOODCOCK WASHBURN LLP
    Inventors: Jerome B. Zeldis, Herbert J. Faleck, Vikram Khetani, Andrew L. Zeitlin, Magsoud M. Dariani, David I. Sterling
  • Publication number: 20020035126
    Abstract: Phenidate drug formulations are provided having reduced potential for drug abuse. Dosage forms for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS are provided which minimize drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential. Such dosage forms comprise D-threo stereoisomer of a phenidate in the substantial absence of all other stereoisomers.
    Type: Application
    Filed: September 18, 2001
    Publication date: March 21, 2002
    Applicant: Celgene Corporation
    Inventors: Andrew L. Zeitlin, Maghsoud M. Dariani
  • Publication number: 20020035090
    Abstract: This invention relates to compositions comprising thalidomide and another anti-cancer drug which can be used in the treatment or prevention of cancer. Preferred anti-cancer drugs are topoisomerase inhibitors. A particular composition comprises thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and irinotecan. The invention also relates to methods of treating or preventing cancer which comprise the administration of a thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of chemotherapy or radiation therapy which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.
    Type: Application
    Filed: May 14, 2001
    Publication date: March 21, 2002
    Inventors: Jerome B. Zeldis, Andrew L. Zeitlin, Sol Barer